Anti-Mouse TIM-2 – Purified in vivo PLATINUM™ Functional Grade

Clone RMT2-25 is commonly used in vivo in mice to functionally block or activate TIM-2, enabling investigation of the immunoregulatory role of TIM-2 in T cell activation, Th2-biased immune responses, and the study of diseases such as allergy, asthma, and autoimmunity.

Researchers employ RMT2-25 in two main types of experimental approaches:

• Functional blocking experiments: These assess how inhibition of TIM-2 affects immune cell activation, cytokine production, and the development or prevention of immune-mediated diseases, such as autoimmune disorders or allergic responses.
• Agonist experiments: These evaluate the effects of stimulating TIM-2, which has been shown to enhance B cell activation and proliferation and regulate Th2 immune responses, providing insights into how TIM-2 influences immune homeostasis.

TIM-2 is primarily expressed on activated T cells (especially those differentiated towards a Th2 phenotype), germinal center B cells, splenic B cells, and select non-hematopoietic cells such as liver and kidney epithelium.

Types of diseases and immunological processes studied using RMT2-25 include:

• Experimental allergy and asthma models, to explore Th2-skewed immunity and airway hypersensitivity.
• Autoimmune disease models (such as arthritis), to evaluate the involvement of TIM-2 in disease development or modulation.
• General T cell activation and regulation studies, focusing on how TIM-2 signaling affects T cell proliferation, cytokine secretion, and adaptive immunity.

Additional details:

• RMT2-25 has been shown to block TIM-2’s interaction with H-ferritin and Semaphorin 4A (Sema4A), which are relevant ligands for the TIM-2 pathway.
• Its use is generally in preclinical immunology research, aiding mechanistic understanding of rodent-specific members of the TIM family.

Alternative uses or application details (such as exact dosage, route, or frequency) depend on specific experimental design and are typically optimized for each study.

In the literature, RMT2-25, which targets TIM-2, is often used alongside other antibodies or proteins that are relevant in immunological studies. Some of these include:

• Anti-TIM-1 (RMT1-17) and Anti-TIM-3 (RMT3-23): These antibodies target other members of the TIM family, which play roles in immune regulation and are studied for their implications in autoimmune diseases and immune responses.

• Anti-TIM-4 (RMT4-53): Another antibody that targets a member of the TIM family, important for understanding the regulatory mechanisms of the immune system.

• Anti-IgM, anti-CD40: These antibodies are used to stimulate B cells, which can interact with TIM-2 in functions like antibody production and cell activation.

These combinations are used to explore the complex interactions within the immune system, particularly focusing on T cell and B cell functions, and how they influence disease states like atopic diseases or autoimmune conditions.

Key Scientific Findings on Clone RMT2-25

RMT2-25 is a rat monoclonal antibody clone that specifically recognizes mouse TIM-2 (T-cell immunoglobulin mucin 2), a cell surface glycoprotein involved in immune regulation. The scientific literature primarily focuses on its functional properties in immunological research, particularly in mouse models.

Functional Blockade of TIM-2

• RMT2-25 demonstrates strong blocking activity against TIM-2 function, outpacing other anti-TIM-2 monoclonal antibodies such as RMT2-14 in this regard.
• Along with clone RMT2-26, RMT2-25 shows stronger blocking activity compared to other clones like RMT2-14. This suggests RMT2-25 is a valuable tool for studying TIM-2-mediated signaling pathways in vivo.

Immunomodulatory Effects

• RMT2-25 (and RMT2-14) can enhance the production of IgG2b and IgG3 by B cells in vitro when co-cultured with anti-IgM, anti-CD40, and IL-4. This effect is not observed with RMT2-26, indicating that RMT2-25 has a distinct immunomodulatory profile.
• These findings suggest that RMT2-25 acts as an agonistic stimulator of TIM-2 on B cells, leading to enhanced B cell activation and antibody production.
• Administration of anti-TIM-2 monoclonal antibodies (including RMT2-25) can exacerbate collagen-induced arthritis (CIA) in mice, likely due to the enhanced activation of B cells and increased antibody production.

Applications and Commercial Use

• RMT2-25 is commercially available as a research reagent (e.g., Leinco, Invitrogen) for the detection and functional modulation of mouse TIM-2 in experimental settings.
• Its specificity and functional properties make it suitable for in vivo applications in immune research, especially studies involving the TIM-2 pathway.

Summary Table: Functional Comparisons of Anti-TIM-2 Clones

Implications

RMT2-25 is a key tool for probing the immunomodulatory functions of TIM-2 in mice. Its ability to block TIM-2 function and enhance B cell responses has provided insights into how TIM-2 regulates immune responses, particularly in autoimmunity models such as collagen-induced arthritis. Its unique properties among anti-TIM-2 clones highlight its value for both mechanistic studies and therapeutic exploration in immune-mediated disorders.

There is no published data on the dosing regimens of clone RMT2-25 across different mouse models in the provided search results. Guides and authoritative dosing references do not list specific regimens for this antibody clone.

Essential context:

• Clone RMT2-25 refers to a monoclonal antibody targeting mouse TIM-2, widely used in immunological research. However, no study in the retrieved results describes its dosing protocols in murine models, regardless of disease context or mouse strain.
• Standard practice for monoclonal antibody treatments in mice (from related antibodies or models) often varies substantially depending on:
  • The purpose (e.g., in vivo blockade vs. cell depletion)
  • Disease model (tumor, autoimmune, infection, etc.)
  • Mouse strain (immunocompetent vs. immunodeficient)
  • Dose range (commonly between 0.1–10 mg/kg for in vivo antibody administration, not RMT2-25-specific)

Additional relevant information:

• In the absence of direct data for RMT2-25, typical approaches include referencing:
  • Published protocols for structurally or functionally similar antibodies, adjusting based on preliminary titrations and observed biological activity.
  • Administration routes (intraperitoneal or intravenous injections are common for monoclonal antibodies in mouse models).
• For any investigational antibody like RMT2-25, pilot dose-finding studies are generally recommended to determine the minimally effective and maximal tolerated dose for each specific mouse model.

Conclusion based on the search results:

• The dosing regimens of clone RMT2-25 in mice are not detailed in existing authoritative sources. Researchers should consult primary literature if new data become available or consider contacting suppliers or original developers for unpublished protocol recommendations. In all cases, pilot testing in the specific mouse model system is required to establish effective and safe dosing.